PHB

Across TCGA pan-cancer cohorts, PHB mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PHB data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PHB mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PHB expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

CCRCC, LSCC, and UCEC are the cancer types where PHB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.358	0.773	.001	39	view →
LSCC	DFS	Median	All	0.999	0.871	.004	24	view →
UCEC	OS	Tertile	III,IV	1.000	0.247	.008	20	view →
PDAC	OS	Quartile	II,III,IV	0.787	0.918	.006	10	view →
LUAD	OS	Quartile	All	0.336	0.848	.004	8	view →
GBM	DFS	Median	All	0.454	0.282	.020	5	view →
HNSC	OS	Quartile	IV	0.801	1.000	.039	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PHB–CCRCC (DFS)

Open the CCRCC breakdown →